SEATTLE--(BUSINESS WIRE)--November 27, 2012--Dendreon Corporation (Nasdaq:DNDN) today announced that management will present at the following conferences:
- 2012 dbAccess BioFEST in Boston, MA, on December 4, 2012, at 2:15 p.m. ET
- 31st Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 7, 2013, at 3:30 p.m. PT
The presentations will be webcast live and available for replay from Dendreon's website, www.dendreon.com. If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.